Which Pharma Executive Made the Most Money Last Year? The Answer May Surprise you! | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Tracking executive pay follows a familiar pattern: Collect compensation disclosures, read said documents as they pile up, and when the usual suspects have all filed their annual reports and proxy statements, put the numbers into a spreadsheet and sort descending.

 

It’s pretty much guaranteed Johnson & Johnson’s CEO will be near the top of the list, regardless who’s in the job. Same for Abbott Laboratories—until it spun off its pharma business, AbbVie, whose CEO is now a regular. Same for Bristol-Myers Squibb—from Jim Cornelius to Lamberto Andreotti and now Giovanni Caforio, M.D.

 

What’s not guaranteed is that the chairman of a generics maker in hot water with the U.S. government and American parents—Mylan’s Robert Coury—would step off the company’s employee roster and into the nonexecutive chairman’s job and reap a $97 million package with the move.

 

Further Reading:

  • The 5 Most Overpaid #Pharma CEOs in the World: http://sco.lt/7XcYlN
  • Some #Biotech CEOs Earned Big Increases in Compensation Even as Their Companies Tanked: http://sco.lt/70MviL 
  • Glaxo to Pay First Woman CEO Less, Cites Lack of Experience: http://sco.lt/67Y7xB 
  • Pharma CEOs Living in an “Alternate Reality” But Getting Paid Exorbitantly High Real World Salaries!: http://sco.lt/7ooZaT 
  • Mylan, EpiPen Price Gouger, Ranks No. 2 in U.S. #Pharma Exec Pay!: http://sco.lt/6lVvf7